Endonovo Therapeutics Files 8K With SEC Regarding SofPulse®

Los Angeles, CA, March 02, 2020 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. ENDV ("Endonovo" or the "Company") today announced it has filed an 8K with the Securities and Exchange Commission (SEC) regarding a presentation on SofPulse^® their companies flagship Electroceutical^® device. The 8K will be utilized to expand the current US market rollout for SofPulse^® and will be presented at various upcoming investment and medical conferences, seminars, presentations and institutional investor meetings.

Endonovo CEO, Alan Collier states, "As part of our current US marketing efforts for SofPulse^® devices, we are making every effort to inform the public about the pain and opioid reduction benefits for SofPulse^®. Filing the 8K with the SEC was a natural progression for getting this accomplished."

SofPulse^® is a FDA Cleared Medical Device, clinically proven to significantly speed the healing process and reduce the need for pain medications. The presentation filed with the SEC provides detailed information on SofPulse^®.

Additional information regarding SofPulse^® can be found at www.sofpulse.com.

About Endonovo Therapeutics Inc.

Endonovo Therapeutics is a commercial-stage developer of noninvasive wearable Electroceuticals^® therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals^® therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (CNS) disorders, including traumatic brain injury (TBI), acute concussions, post-concussion syndrome and multiple sclerosis. The Company's noninvasive Electroceutical^® therapeutic device, SofPulse^®, which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA-cleared and CE marked for the palliative treatment of soft tissue injuries and post-operative pain and edema and has CMS national coverage for the treatment of chronic wounds. The Company's current portfolio of preclinical-stage Electroceuticals^® therapeutic devices addresses chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's noninvasive, wearable Electroceuticals^® therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com.

Safe Harbor Statement

This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.

Investor Relations Contact:

Endonovo Therapeutics, Inc.
Mr. Andrew Barwicki
516-662-9461
Andrew@barwicki.com
www.endonovo.com